No might issues put forth for Tuesday FDA admonitory commission
Prcis records in push of an FDA admonitory board fittings Tuesday to reflect on adding an portent for GLP-1 inhibitor panacea liraglutide (Victoza) to alter the risk of remarkable adverse cardiovascular episodes in high-risk of maturities with species 2 diabetes tip ated teensy-weensy nicety with the patronage trial or computes.
Specifically, the broached indication for the glucagon-like peptide-1 (GLP-1) indistinct would be “as an adjunct to post treatment of cardiovascular probability factors to Remedy set the risk of big adverse cardiovascular sequels (cardiovascular decease, non-fatal myocardial infarction, or non-fatal rejections) in adults with species 2 diabetes mellitus and supreme cardiovascular jeopardy.”
Loading...